Sheldon H. Preskorn, MD

  • 18Articles
  • 72.7KReads1
  • 1997–2022Active
  • 50Collaborators
  • 309Citations2

About

Sheldon H. Preskorn, MD, affiliated with Kansas University School of Medicine-Wichita, has authored 18 articles between 1997 and 2022. His publications focus on schizophrenia, schizoaffective disorders, major depressive disorder, bipolar disorder, psychopharmacology, and genetics within psychiatry. Notable topics include clinical trials of treatments for acute agitation and treatment-resistant depression, pharmacokinetic drug interactions, personalized medicine, and pharmacologic principles in antipsychotic use.

Publications

JCP
Sublingual Dexmedetomidine for Agitation in Schizophrenia
Original Research

Sublingual Dexmedetomidine for Agitation in Schizophrenia

October 3, 2022

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or schizoaffective disorder.
, , , et al
JCP
Esketamine Nasal Spray and Adverse Events Over Time
Original Research

Esketamine Nasal Spray and Adverse Events Over Time

September 19, 2022

This study looked at the occurrence and severity of adverse events over time with esketamine nasal spray in MDD patients also receiving an oral antidepressant.
, , , et al
JCP
Commentary

Creatinine Clearance Estimation, Package Inserts, and Therapeutic Drug Monitoring

November 26, 2019

This commentary discusses the findings and implications of a recent study by Gründer et al and also highlights the importance of following formulas to estimate creatinine clearance, reading package...
JCP
Original Research

High False-Positive Rate of a Putative Biomarker Test to Aid in the Diagnosis of Schizophrenia

April 27, 2016

,
PCC
Article

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example

March 19, 2015

How do you avoid drug-drug interactions in your patients who are taking multiple medications? This article explains the process for assessing the risk of a drug causing or being...
, ,
JCP
Letter to the Editor

Dr Preskorn Replies

October 15, 2013

JCP
Original Research

Cytochrome P450 2D6 Phenoconversion Is Common in Patients Being Treated for Depression: Implications for Personalized Medicine

March 13, 2013

, , , et al
JCP
Commentary

Changes in the Product Label for Pimozide Illustrate Both the Promises and the Challenges of Personalized Medicine

September 15, 2012

JCP
Original Research

Cytochrome P450 2D6 Phenotype Predicts Antidepressant Efficacy of Venlafaxine: A Secondary Analysis of 4 Studies in Major Depressive Disorder

April 13, 2010

, , , et al
JCP
Academic Highlights

A Roadmap to Key Pharmacologic Principles in Using Antipsychotics: Application in Clinical Practice

April 15, 2009

JCP
Original Research

The Impact of Calories and Fat Content of Meals on Oral Ziprasidone Absorption: A Randomized, Open-Label, Crossover Trial

October 21, 2008

, , , et al
JCP
Letter to the Editor

Reply to "Intrinsic Activity of Aripiprazole Is Not 30% of Dopamine, But Only About 6% Under Ideal Antipsychotic Therapy"

May 11, 2008

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe